Brain Cancer - Pipeline Review, H2 2015

Date: October 21, 2015
Pages: 311
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B52A71CE372EN
Leaflet:

Download PDF Leaflet

Brain Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H2 2015’, provides an overview of the Brain Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Brain Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Brain Cancer Overview
Therapeutics Development
Pipeline Products for Brain Cancer - Overview
Pipeline Products for Brain Cancer - Comparative Analysis
Brain Cancer - Therapeutics under Development by Companies
Brain Cancer - Therapeutics under Investigation by Universities/Institutes
Brain Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Brain Cancer - Products under Development by Companies
Brain Cancer - Products under Investigation by Universities/Institutes
Brain Cancer - Companies Involved in Therapeutics Development
2-BBB MEDICINES BV
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
AngioChem Inc.
Arrien Pharmaceuticals, LLC
BeiGene(Beijing) Co.,Ltd
Berg, LLC
biOasis Technologies Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cavion LLC
Critical Outcome Technologies Inc.
CureFAKtor Pharmaceuticals, LLC
Diffusion Pharmaceuticals LLC
e-Therapeutics Plc
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
Komipharm International Co., Ltd.
Lipocure Ltd.
Medicenna Therapeutics, Inc
MEI Pharma, Inc.
NatureWise Biotech & Medicals Corporation
Nektar Therapeutics
Nerviano Medical Sciences S.r.l.
Novartis AG
Novogen Limited
Oncology Research International Limited
Oncolytics Biotech Inc.
Oncothyreon Inc.
Pfizer Inc.
Philogen S.p.A.
Phosplatin Therapeutics LLC
Prana Biotechnology Limited
Progenics Pharmaceuticals, Inc.
Puma Biotechnology, Inc.
Radius Health, Inc.
Sanofi
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Tocagen Inc.
ViraTherapeutics GmbH
Zymeworks Inc.
Brain Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
(topotecan hydrochloride + vincristine sulfate) - Drug Profile
2B3-101 - DRUG PROFILE
Actimab-Br - Drug Profile
afatinib dimaleate - Drug Profile
ANG-1005 - Drug Profile
ANG-4043 - Drug Profile
ARN-7016 - Drug Profile
BGBA-317 - Drug Profile
BT-2111 - Drug Profile
cabazitaxel - Drug Profile
cabozantinib s-malate - Drug Profile
Cell Therapy to Target CD133 for Refractory and Relapsed Malignancies - Drug Profile
ceritinib - Drug Profile
CFAKC-4 - Drug Profile
cobimetinib fumarate - Drug Profile
COTI-2 - Drug Profile
dacomitinib - Drug Profile
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Edotreotide Labeled Yttrium 90 - Drug Profile
etirinotecan pegol - Drug Profile
ETS-2101 - Drug Profile
Gene Therapy for Brain Cancer - Drug Profile
HMPL-813 - Drug Profile
ipilimumab - Drug Profile
irbinitinib - Drug Profile
irinotecan hydrochloride + TBio-02 - Drug Profile
KML-001 - Drug Profile
LEQ-506 - Drug Profile
lorlatinib - Drug Profile
lucanthone hydrochloride - Drug Profile
MDNA-55 - Drug Profile
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile
NBM-01 - Drug Profile
neratinib - Drug Profile
nimotuzumab - Drug Profile
NMSE-973 - Drug Profile
NOV-202 - Drug Profile
ORIL-007 - Drug Profile
PB-357 - Drug Profile
PBT-519 - Drug Profile
pelareorep - Drug Profile
pracinostat - Drug Profile
PT-112 - Drug Profile
RAD-1901 - Drug Profile
radretumab - Drug Profile
RRX-001 - Drug Profile
siomycin A - Drug Profile
SL-301 - Drug Profile
SL-302 - Drug Profile
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
Small Molecule for Glioblastomas - Drug Profile
Small Molecule to Agonize GPR55 for Oncology - Drug Profile
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
THR-317 - Drug Profile
TPI-287 - Drug Profile
transcrocetinate sodium - Drug Profile
Trilexium - Drug Profile
TTL-1177 - Drug Profile
ubidecarenone - Drug Profile
Vaccine for Cancer - Drug Profile
Vaccine for Glioblastoma Multiforme - Drug Profile
veliparib - Drug Profile
VMY-1103 - Drug Profile
vocimagene amiretrorepvec + flucytosine ER - Drug Profile
ZW-39 - Drug Profile
Brain Cancer - Recent Pipeline Updates
Brain Cancer - Dormant Projects
Brain Cancer - Discontinued Products
Brain Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Brain Cancer, H2 2015
Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Brain Cancer - Pipeline by 2-BBB Medicines BV, H2 2015
Brain Cancer - Pipeline by AbbVie Inc., H2 2015
Brain Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Brain Cancer - Pipeline by AngioChem Inc., H2 2015
Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Brain Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Brain Cancer - Pipeline by Berg, LLC, H2 2015
Brain Cancer - Pipeline by biOasis Technologies Inc., H2 2015
Brain Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Brain Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Brain Cancer - Pipeline by Cavion LLC, H2 2015
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
Brain Cancer - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
Brain Cancer - Pipeline by e-Therapeutics Plc, H2 2015
Brain Cancer - Pipeline by Exelixis, Inc., H2 2015
Brain Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Brain Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
Brain Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
Brain Cancer - Pipeline by Lipocure Ltd., H2 2015
Brain Cancer - Pipeline by Medicenna Therapeutics, Inc, H2 2015
Brain Cancer - Pipeline by MEI Pharma, Inc., H2 2015
Brain Cancer - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
Brain Cancer - Pipeline by Nektar Therapeutics, H2 2015
Brain Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
Brain Cancer - Pipeline by Novartis AG, H2 2015
Brain Cancer - Pipeline by Novogen Limited, H2 2015
Brain Cancer - Pipeline by Oncology Research International Limited, H2 2015
Brain Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Brain Cancer - Pipeline by Oncothyreon Inc., H2 2015
Brain Cancer - Pipeline by Pfizer Inc., H2 2015
Brain Cancer - Pipeline by Philogen S.p.A., H2 2015
Brain Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015
Brain Cancer - Pipeline by Prana Biotechnology Limited, H2 2015
Brain Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015
Brain Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Brain Cancer - Pipeline by Radius Health, Inc., H2 2015
Brain Cancer - Pipeline by Sanofi, H2 2015
Brain Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015
Brain Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Brain Cancer - Pipeline by Tocagen Inc., H2 2015
Brain Cancer - Pipeline by ViraTherapeutics GmbH, H2 2015
Brain Cancer - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Brain Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Brain Cancer - Dormant Projects, H2 2015
Brain Cancer - Dormant Projects (Contd..1), H2 2015
Brain Cancer - Dormant Projects (Contd..2), H2 2015
Brain Cancer - Dormant Projects (Contd..3), H2 2015
Brain Cancer - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Brain Cancer, H2 2015
Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Brain Tumor - Pipeline Review, H2 2014 US$ 1,500.00 Jul, 2014 · 90 pages
Brain Metastasis - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 194 pages
Brain Edema - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 44 pages
Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages

Ask Your Question

Brain Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: